Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company making regenerated organs for transplant. The Company's product, the HART-Trachea, is intended to be used to restore the structure and/or function of a severely damaged trachea (windpipe). The HART-Trachea comprises the patient's own bone marrow cells seeded on the Company's InBreath porous plastic scaffold in its InBreath organ bioreactor. Its HART-Trachea addresses both of the challenges to trachea transplant, such as the shortage of suitable donor tracheas and the risk and expense of lifelong anti-rejection drug therapy. The Company has received orphan drug designation from the United States Food and Drug Administration (FDA) for the HART-Trachea in the United States market. The Company is engaged in pre-clinical development of its HART-Trachea.